Victoza FDA Approval History
Last updated by Judith Stewart, BPharm on June 17, 2019.
Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Development Timeline for Victoza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.